

# Piotr Jã³zef Rudzki

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4608600/publications.pdf>

Version: 2024-02-01

32  
papers

414  
citations

840776

11  
h-index

752698

20  
g-index

33  
all docs

33  
docs citations

33  
times ranked

539  
citing authors

#	ARTICLE	IF	CITATIONS
1	Replicates Number for Drug Stability Testing during Bioanalytical Method Validation – An Experimental and Retrospective Approach. <i>Molecules</i> , 2022, 27, 457.	3.8	1
2	Evaluation of tramadol human pharmacokinetics and safety after co-administration of magnesium ions in randomized, single- and multiple-dose studies. <i>Pharmacological Reports</i> , 2021, 73, 604-614.	3.3	2
3	Combined Protein and Alkaloid Research of <i>Chelidonium majus</i> Latex Reveals CmMLP1 Accompanied by Alkaloids with Cytotoxic Potential to Human Cervical Carcinoma Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11838.	4.1	5
4	Low-oxidation-potential thiophene-carbazole monomers for electro-oxidative molecular imprinting: Selective chemosensing of aripiprazole. <i>Biosensors and Bioelectronics</i> , 2020, 169, 112589.	10.1	15
5	10th Anniversary of a Two-Stage Design in Bioequivalence. Why Has it Still Not Been Implemented?. <i>Pharmaceutical Research</i> , 2020, 37, 140.	3.5	3
6	Visualizing bioanalytical methods – a near or distant future?. <i>Bioanalysis</i> , 2020, 12, 427-429.	1.5	1
7	ORBIS (Open Research Biopharmaceutical Internships Support) – building bridges between academia and pharmaceutical industry to improve drug development. <i>Journal of Medical Science</i> , 2020, 89, e419.	0.7	1
8	Incurred Sample Reanalysis: Time to Change the Sample Size Calculation?. <i>AAPS Journal</i> , 2019, 21, 28.	4.4	12
9	Bioanalytical method validation: new FDA guidance vs. EMA guideline. Better or worse?. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 165, 381-385.	2.8	103
10	Matrix effect screening for cloud-point extraction combined with liquid chromatography coupled to mass spectrometry: Bioanalysis of pharmaceuticals. <i>Journal of Chromatography A</i> , 2019, 1591, 44-54.	3.7	14
11	Quantitative evaluation of the matrix effect in bioanalytical methods based on LC-MS: A comparison of two approaches. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 155, 314-319.	2.8	35
12	Extended 3D and 4D cumulative plots for evaluation of unmatched incurred sample reanalysis. <i>Bioanalysis</i> , 2018, 10, 153-162.	1.5	4
13	Is a deuterated internal standard appropriate for the reliable determination of olmesartan in human plasma?. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1040, 53-59.	2.3	8
14	Comprehensive graphical presentation of data from incurred sample reanalysis. <i>Bioanalysis</i> , 2017, 9, 947-956.	1.5	13
15	Incurred sample reanalysis: adjusted procedure for sample size calculation. <i>Bioanalysis</i> , 2017, 9, 1719-1726.	1.5	7
16	Bioequivalence study of 2.5 mg film-coated bisoprolol tablets in healthy volunteers. <i>Kardiologia Polska</i> , 2017, 75, 48-54.	0.6	5
17	ENVIRONMENTALLY FRIENDLY LC/MS DETERMINATION OF EPLERENONE IN HUMAN PLASMA. <i>Acta Poloniae Pharmaceutica</i> , 2016, 73, 1487-1493.	0.1	2
18	HPLC-UV ASSAY OF IMATINIB IN HUMAN PLASMA OPTIMIZED FOR BIOEQUIVALENCE STUDIES. <i>Acta Poloniae Pharmaceutica</i> , 2016, 73, 1495-1503.	0.1	4

#	ARTICLE	IF	CITATIONS
19	Cloud-point extraction is compatible with liquid chromatography coupled to electrospray ionization mass spectrometry for the determination of bisoprolol in human plasma. <i>Journal of Chromatography A</i> , 2015, 1423, 39-46.	3.7	21
20	Bioequivalence Study of 8mg Ondansetron Film-coated Tablets in Healthy Caucasian Volunteers. <i>Drug Research</i> , 2014, 64, 220-224.	1.7	1
21	Determination of sunitinib in human plasma using liquid chromatography coupled with mass spectrometry. <i>Journal of Separation Science</i> , 2014, 37, 2652-2658.	2.5	15
22	Simplified LC-MS/MS method enabling the determination of azithromycin in human plasma after a low 100 mg dose administration. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 100, 184-189.	2.8	23
23	Determination of duloxetine in human plasma with proven lack of influence of the major metabolite 4-hydroxyduloxetine. <i>Clinical Biochemistry</i> , 2014, 47, 1313-1315.	1.9	4
24	Sensitive single quadrupole LC/MS method for determination of lapatinib in human plasma. <i>Acta Poloniae Pharmaceutica</i> , 2014, 71, 1029-36.	0.1	6
25	Bioequivalence and pharmacokinetics of two 10-mg bisoprolol formulations as film-coated tablets in healthy white volunteers: a randomized, crossover, open-label, 2-period, single-dose, fasting study. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2012, 50, 909-19.	0.6	4
26	Bioequivalence study of 500 mg cefuroxime axetil film-coated tablets in healthy volunteers. <i>Acta Poloniae Pharmaceutica</i> , 2012, 69, 1356-63.	0.1	3
27	Development and validation of a sensitive liquid chromatography/tandem mass spectrometry method for the determination of exemestane in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2011, 879, 1905-1910.	2.3	6
28	Validated HPLC method for determination of cefuroxime in human plasma. <i>Acta Poloniae Pharmaceutica</i> , 2010, 67, 677-81.	0.1	2
29	Application of confidence intervals to bioanalytical method validation--drug stability in biological matrix testing. <i>Acta Poloniae Pharmaceutica</i> , 2008, 65, 743-7.	0.1	9
30	An overview of chromatographic methods coupled with mass spectrometric detection for determination of angiotensin-converting enzyme inhibitors in biological material. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2007, 44, 356-367.	2.8	18
31	Determination of clopidogrel metabolite (SR26334) in human plasma by LC-MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2006, 41, 533-539.	2.8	61
32	Validated LC-MS method for determination of tamsulosin in human plasma and its application to pharmacokinetic study. <i>Acta Poloniae Pharmaceutica</i> , 2006, 63, 417-9.	0.1	3